Skip to main content
. 2020 Jan 29;183(2):276–284. doi: 10.1111/bjd.18634

Figure 4.

Figure 4

Predicted rates of a Psoriasis Area and Severity Index 90 treatment response for guselkumab and ustekinumab, based on data from the VOYAGE, NAVIGATE and PHOENIX trials, with 95% confidence intervals. Predicted rates were derived from the multivariable logistic regression model, as described in the study methods. CI, confidence interval; GUS, guselkumab; PASI, Psoriasis Area and Severity Index; UST, ustekinumab.